SCHEMBL23163602

SCHEMBL23163602

O=C(O)C1(c2ccc(OCCc3ccccc3)cc2)CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
FFAR1 O14842 5/20 0.51
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
LMNA P02545 2/20 0.44
CYP2C19 P33261 2/20 0.44
ALDH1A1 P00352 3/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23163981 0.94 MEN1 (0.55) TSHRMEN1KMT2AFFAR1RAB9A
SCHEMBL23163698 0.88 LMNA (0.49) TSHRMEN1KMT2AFFAR1RAB9A
SCHEMBL23163539 0.87 MMP1 (0.53) TSHRMEN1KMT2AFFAR1MAOB
SCHEMBL23164095 0.82 LMNA (0.48) TSHRMEN1KMT2AFFAR1RAB9A
SCHEMBL23164236 0.79 KMT2A (0.52) TSHRMEN1KMT2ALMNACYP2C19
SCHEMBL23164180 0.78 MEN1 (0.54) TSHRMEN1KMT2AHPGD
SCHEMBL28749427 0.77 GPR132 (0.47) TSHRMEN1KMT2ARAB9AHTT
SCHEMBL31582061 0.77 PARP10 (0.52) FFAR1MAOBLMNACYP2C19ALDH1A1
SCHEMBL1627580 0.77 AKR1C1 (0.68) TSHRKMT2ARAB9ANPC1LMNA
SCHEMBL3271588 0.77 HRH3 (0.69) TSHRMEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists DOMAIN THERAPEUTICS (FR) 2026-01-20 US disclosed
EP-4038052-B1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2024-02-07 EP disclosed
US-20220378772-A1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2022-12-01 US disclosed
EP-4038052-A2 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS Domain Therapeutics (FR) 2022-08-10 EP disclosed
WO-2021064189-A2 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2021-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists PTGER1, PTGER4, PTGER3 TSHR 606/4885MEN1 3795/4885KMT2A 3563/4885
US-20220378772-A1 PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS PTGER4, PTGER1, PTGER2 TSHR 960/4885MEN1 3666/4885KMT2A 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.